Rigel Pharma has 2 FDA-approved drugs: Tavalisse for chronic immune thrombocytopenia (ITP) and Rezlidhia for relapsed or refractory AML with susceptible IDH1 mutation. In Q4 2022, Tavalisse revenue ...
SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL), Inc. today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical ...
SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback